Press release
Antibody-mediated Rejection Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | CSL Behring, Hansa Biopharma, Horizon Therapeutics, Sanofi, Farsad Eskandary, CSL Behring, Bristol
To Know in detail about the Antibody-mediated Rejection market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Antibody-mediated Rejection Market Forecast
https://www.delveinsight.com/sample-request/antibody-mediated-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Antibody-mediated Rejection Market Report:
• The Antibody-mediated Rejection market size was valued approximately USD 85 million in 2019 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In March 2024, Human Immunology Biosciences (HI-Bio™), a biotech firm in the clinical stage, specializing in tailored treatments for individuals grappling with severe immune-mediated disorders (IMDs), has revealed that the U.S. Food and Drug Administration (FDA) has conferred Orphan Drug Designation (ODD) upon felzartamab. This designation is specifically for addressing antibody-mediated rejection (AMR) in recipients of kidney transplants.
• The incidence of Antibody-mediated Rejection in kidney transplants was highest in the United States. According to DelveInsight's predictions, the number of kidney transplants performed nationwide in 2019 was 1,887; this number is projected to rise to 2,032 by 2032
• France had the most antibody-mediated rejection (AMR) instances among the European nations in 2019 with 459 cases, followed by Spain with 419 cases. Germany, on the other side, had the lowest number in 2019, with 259 cases
• Key Antibody-mediated Rejection Companies: CSL Behring, Hansa Biopharma, Horizon Therapeutics, Sanofi, Farsad Eskandary, Bristol-Myers Squibb, Janssen, LP, Alexion, and others
• Key Antibody-mediated Rejection Therapies: Clazakizumab, Imlifidase, VIB4920 (HZN-4920), Felzartamab, Physiologic saline solution, Belatacept, Daratumumab, BIVV020 (SAR445088), Nulojix (Belatacept), Eculizumab, and others
• The Antibody-mediated Rejection epidemiology based on gender analyzed that both males and females are affected equally by Antibody-mediated Rejection
• The Antibody-mediated Rejection market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Antibody-mediated Rejection pipeline products will significantly revolutionize the Antibody-mediated Rejection market dynamics.
Antibody-mediated Rejection Overview
A severe post-kidney transplant complication known as antibody-mediated rejection (AMR) causes both short- and long-term damage to transplant recipients. Even with desensitization methods in place, up to one-third of extremely sensitive patients still run the risk of developing acute AMR after transplant.
Get a Free sample for the Antibody-mediated Rejection Market Report:
https://www.delveinsight.com/report-store/antibody-mediated-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Antibody-mediated Rejection Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Antibody-mediated Rejection Epidemiology Segmentation:
The Antibody-mediated Rejection market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Antibody-mediated Rejection
• Prevalent Cases of Antibody-mediated Rejection by severity
• Gender-specific Prevalence of Antibody-mediated Rejection
• Diagnosed Cases of Episodic and Chronic Antibody-mediated Rejection
Download the report to understand which factors are driving Antibody-mediated Rejection epidemiology trends @ Antibody-mediated Rejection Epidemiology Forecast
https://www.delveinsight.com/sample-request/antibody-mediated-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Antibody-mediated Rejection Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Antibody-mediated Rejection market or expected to get launched during the study period. The analysis covers Antibody-mediated Rejection market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Antibody-mediated Rejection Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Antibody-mediated Rejection Therapies and Key Companies
• Clazakizumab: CSL Behring
• Imlifidase: Hansa Biopharma
• VIB4920 (HZN-4920): Horizon Therapeutics
• Felzartamab: Farsad Eskandary
• Physiologic saline solution: CSL Behring
• Belatacept: Bristol-Myers Squibb
• Daratumumab: Janssen, LP
• BIVV020 (SAR445088): Sanofi
• Nulojix (Belatacept): Bristol-Myers Squibb
• Eculizumab: Alexion
Discover more about therapies set to grab major Antibody-mediated Rejection market share @ Antibody-mediated Rejection Treatment Market
https://www.delveinsight.com/sample-request/antibody-mediated-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Antibody-mediated Rejection Market Drivers
• Emerging Therapy
• Development of Personalized Therapy
• Targeting of Novel Pathways
• Increased Rate of Organ Donation
• Development of Gene therapy
Antibody-mediated Rejection Market Barriers
• Challenges in Designing Clinical Trials
• Need for Evidence-based Treatment Guidelines
• High Clinical Burden
Scope of the Antibody-mediated Rejection Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Antibody-mediated Rejection Companies: CSL Behring, Hansa Biopharma, Horizon Therapeutics, Sanofi, Farsad Eskandary, Bristol-Myers Squibb, Janssen, LP, Alexion, and others
• Key Antibody-mediated Rejection Therapies: Clazakizumab, Imlifidase, VIB4920 (HZN-4920), Felzartamab, Physiologic saline solution, Belatacept, Daratumumab, BIVV020 (SAR445088), Nulojix (Belatacept), Eculizumab, and others
• Antibody-mediated Rejection Therapeutic Assessment: Antibody-mediated Rejection current marketed and Antibody-mediated Rejection emerging therapies
• Antibody-mediated Rejection Market Dynamics: Antibody-mediated Rejection market drivers and Antibody-mediated Rejection market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Antibody-mediated Rejection Unmet Needs, KOL's views, Analyst's views, Antibody-mediated Rejection Market Access and Reimbursement
To know more about Antibody-mediated Rejection companies working in the treatment market, visit @ Antibody-mediated Rejection Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/antibody-mediated-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Antibody-mediated Rejection Market Report Introduction
2. Executive Summary for Antibody-mediated Rejection
3. SWOT analysis of Antibody-mediated Rejection
4. Antibody-mediated Rejection Patient Share (%) Overview at a Glance
5. Antibody-mediated Rejection Market Overview at a Glance
6. Antibody-mediated Rejection Disease Background and Overview
7. Antibody-mediated Rejection Epidemiology and Patient Population
8. Country-Specific Patient Population of Antibody-mediated Rejection
9. Antibody-mediated Rejection Current Treatment and Medical Practices
10. Antibody-mediated Rejection Unmet Needs
11. Antibody-mediated Rejection Emerging Therapies
12. Antibody-mediated Rejection Market Outlook
13. Country-Wise Antibody-mediated Rejection Market Analysis (2019-2032)
14. Antibody-mediated Rejection Market Access and Reimbursement of Therapies
15. Antibody-mediated Rejection Market Drivers
16. Antibody-mediated Rejection Market Barriers
17. Antibody-mediated Rejection Appendix
18. Antibody-mediated Rejection Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Antibody-mediated Rejection Epidemiology https://www.delveinsight.com/report-store/antibody-mediated-rejection-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Antibody-mediated Rejection Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Antibody-mediated Rejection epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Cancer Diagnostics Market
https://www.delveinsight.com/report-store/cancer-diagnostic-market
Cancer Diagnostics Market By Type (Product Type [Reagent & Kits and Instruments], and Services), Technique (Molecular Diagnostics [Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Fluorescent In-Situ Hybridization (FISH), Microarray, and Immunohistochemistry], Diagnostics Imaging [Ultrasound & Radiology, Mammography, MRI Scan, CT Scan, and Nuclear Medicine Scans], Endoscopy, and Biopsy [Standard Biopsy and Liquid Biopsy]), Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, and Others), End-User (Hospitals, Diagnostics Labs, and Others), and Geography, is expected to grow at a significant CAGR forecast till 2028 owing to the growing burden of cancer across the globe and rise in various product launches for efficient detection of cancer.
Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to lauch of advanced devices and increasing prevalence of respiratory diseases such as COPD.
Zika Virus Market
https://www.delveinsight.com/report-store/zika-virus-market
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Systemic Sclerosis Market
https://www.delveinsight.com/report-store/systemic-sclerosis-market
DelveInsight's "Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes Systemic Sclerosis. The report includes a detailed examination of the historical and projected epidemiology data that includes diagnosed prevalent cases of Systemic Sclerosis segmented by gender-specific, age-specific, and type-specific cases.
Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.
Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.
Bladder Scanners Market
https://www.delveinsight.com/report-store/bladder-scanners-market
"DelveInsight's 'Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Antibody-mediated Rejection Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | CSL Behring, Hansa Biopharma, Horizon Therapeutics, Sanofi, Farsad Eskandary, CSL Behring, Bristol here
News-ID: 3466257 • Views: …
More Releases from DelveInsight Business Research
Vitiligo Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA App …
The "Vitiligo Pipeline Insight, 2025" report by DelveInsight delivers an in-depth view of the current clinical development scenario along with the future growth trajectory of the Vitiligo Market.
As per DelveInsight's evaluation, the global Vitiligo treatment pipeline features 20+ leading companies actively engaged in developing 20+ therapeutic candidates. The analysis covers Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and developmental updates.
The Vitiligo Pipeline report offers extensive commercial and clinical…
Myelodysplastic Syndrome Competitive Landscape 2025: Clinical Trial Analysis, Th …
DelveInsight's, "Myelodysplastic Syndrome Pipeline Insight 2025" report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Myelodysplastic Syndrome Pipeline Report
• DelveInsight's Myelodysplastic Syndrome…
Fibromyalgia Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA …
According to DelveInsight, the global Fibromyalgia pipeline features more than eight key companies actively developing over ten treatment candidates. The analysis encompasses ongoing clinical trials, therapeutic mechanisms of action, routes of administration, and recent developments within the Fibromyalgia treatment landscape.
The Fibromyalgia Pipeline 2025 report provides an exhaustive evaluation of pipeline products, ranging from preclinical stages to marketed therapies. It includes comprehensive details on each drug's mechanism of action, clinical trial…
Chronic Wounds Competitive Landscape 2025: Clinical Trial Analysis, Therapies, F …
As per DelveInsight's assessment, globally, Chronic Wounds pipeline constitutes 7+ key companies continuously working towards developing 8+ Chronic Wounds treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Chronic Wounds Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Wounds Market.
The Chronic Wounds Pipeline report embraces in-depth commercial and clinical assessment…
More Releases for Rejection
Antibody-mediated Rejection Market Dynamics, Innovations and Growth
Organ transplantation has been one of the most remarkable achievements of modern medicine, offering patients with end-stage organ failure a renewed chance at life. However, antibody-mediated rejection (AMR) remains a major complication following kidney, heart, lung, and liver transplants, significantly affecting long-term graft survival. AMR occurs when donor-specific antibodies (DSAs) attack the transplanted organ, leading to immune injury and often graft loss.
Download Full PDF Sample Copy of Market Report @…
Global Nitrogen Rejection Units Market Analysis (2024-2029)
LPI (LP Information)' newest research report, the "Nitrogen Rejection Units Industry Forecast" looks at past sales and reviews total world Nitrogen Rejection Units sales in 2024, providing a comprehensive analysis by region and market sector of projected Nitrogen Rejection Units sales for 2024 through 2029. With Nitrogen Rejection Units sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world…
Transplant Rejection Treatment Market-Forecast to 2026
According to a new market research report published by Global Market Estimates, the Global Transplant Rejection Treatment Market is projected to grow from USD 5.6 billion in 2021 to USD 6.9 billion by 2026 at a CAGR value of 4.2% from 2021 to 2026.
Increasing number of research and developmental activities related to transplant rejection procedure, increasing demand for transplant surgeries, rising chronic disease prevalence and high disposable income are…
Bone Marrow Transplant Rejection - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Bone Marrow Transplant Rejection - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Marrow Transplant Rejection - Pipeline Review, H1 2017, provides an overview of the Bone Marrow Transplant Rejection (Immunology) pipeline landscape.
Bone marrow transplant rejection is a complication that can occur after a stem…
Jobbatical brings candidate rejection messaging to Jobbatical.com
Tallinn, Estonia – June 8, 2017 – Jobbatical product innovation continues with the ability to send rejection messaging to candidates directly from our platform.
Jobbatical continues to make it easier for hiring managers to source and evaluate applicants on our platform. Now we’ve implemented an easy to use rejection function with the option to use a template letter or personalized response to reject the candidate. As a hiring manager, it’s…
Liver Transplant Rejection - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Liver Transplant Rejection - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Transplant Rejection - Pipeline Review, H1 2017, provides an overview of the Liver Transplant Rejection (Immunology) pipeline landscape.
Liver transplantation is the conventional therapy used in various liver diseases. Liver has the unique ability…
